[Back to Papers in Press] [Back to Biochemistry (Moscow) Home page]
[Download Reprint (PDF)]

Biochemistry (Moscow). Papers in Press. Published on April 29, 2019 as Manuscript BM18-359.

A New Efficient Method for Production of Recombinant Antitumor Cytokine TRAIL and Its Receptor-Selective Variant DR5-B

A. V. Yagolovich1,2, A. A. Artykov1,2, D. A. Dolgikh1,2, M. P. Kirpichnikov1,2, and M. E. Gasparian1,a*

1Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia

2Lomonosov Moscow State University, Faculty of Biology, 119991 Moscow, Russia

*To whom correspondence should be addressed.

Received December 19, 2018; Revised February 25, 2019; Accepted February 26, 2019
The cytokine TRAIL induces apoptosis in tumor cells of various origin without affecting normal cells. Clinical trials of TRAIL-receptor (DR4 and DR5) agonists (recombinant TRAIL or death receptors antibodies) have largely failed because most human tumors were resistant to them. Currently, a second generation of agents targeted at TRAIL-R with increased efficiency has been developed. To this end, we have developed DR5-B, a variant of TRAIL selectively interacting with DR5. We have developed a new efficient method for production of TRAIL and DR5-B using expression of these proteins in Escherichia coli strain SHuffle B. The proteins were isolated from the cytoplasmic fraction of cells and purified to a high degree of homogeneity using metal-affinity and ion-exchange chromatography. The protein yield was 211 and 173 mg from one liter of cell culture for DR5-B and TRAIL, respectively, which significantly exceeded the results obtained by other methods. DR5-B killed tumor cells of different origin more efficiently and rapidly compared with TRAIL. The resulting preparations can be used for the study of TRAIL signaling pathways and in preclinical and clinical trials as antitumor agents.
KEY WORDS: cytokine TRAIL, mutant variant DR5-B, strain E. coli SHuffle B, cancer therapy